The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
Abstract Background Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them have concerned the recurrence risk...
Guardado en:
Autores principales: | Yunzhi Zou, Depei Li, Jiayu Gu, Siyu Chen, Xia Wen, Jiajun Dong, Xiaobing Jiang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/017de2a0a1a64c9aa4461a58e0795625 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
por: Shuman Wang, et al.
Publicado: (2021) -
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment
por: Rosa Pirchio, et al.
Publicado: (2021) -
Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina
por: Cuevas,José Luis, et al.
Publicado: (2013) -
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via MA
Publicado: (2010) -
Efficacy and Cerebrospinal Fluid Rhinorrhea after Cabergoline Treatment in Patients with Bioactive Macroprolactinoma
por: Hae-Kyung Kim, et al.
Publicado: (2021)